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Polypeptide hormones and steroid hormones, either expressed by the placenta or dependant 10 
on the placenta for their synthesis, are key to driving adaptations in the mother during 11 
pregnancy that support growth in utero. These adaptations include changes in maternal 12 
behaviour that take place in pregnancy and after the birth  to ensure that offspring receive 13 
appropriate care and nutrition. Placentally-derived hormones implicated in the programming 14 
of maternal caregiving in rodents include prolactin-related hormones and steroid hormones. 15 
Neuromodulators produced by the placenta may act directly on the fetus to support brain 16 
development. A number of imprinted genes function antagonistically in the placenta to regulate 17 
the development of key placental endocrine lineages expressing these hormones. Gain-in-18 
expression of the normally maternally expressed gene Phlda2 or loss-of-function of the 19 
normally paternally expressed gene Peg3 results in fewer endocrine cells in the placenta, and 20 
pups are born low birth weight. Importantly, wild type dams carrying these genetically altered 21 
pups display alterations in their behaviour with decreased focus on nurturing (Phlda2) or 22 
heightened anxiety (Peg3). These same genes may regulate placental hormones in human 23 
pregnancies, with the potential to influence birth weight and maternal mood. Consequently, 24 
the aberrant expression of imprinted genes in the placenta may underlie the reported co-25 
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Women are at high risk of developing mood symptoms in pregnancy with one in seven women 39 
reporting clinically concerning symptoms of depression [1-3]. Depression in pregnancy is 40 
commonly comorbid with anxiety [4] and these mood disorders have both been linked to a 41 
higher risk of low birth weight and difficulties in infant development including emotional and 42 
behavioural problems, cognitive impairment and psychopathology [5]. Despite considerable 43 
epidemiological data reporting links between these exposures and outcomes, the 44 
underpinning biological mechanisms are unknown nor can we currently predict specific 45 
outcomes. Progress is hampered because the causes and consequences of maternal mood 46 
disorders are complex. There are multiple environmental and genetic components, exposure 47 
can be prenatal and/or postnatal, and many studies rely on questionnaires completed by 48 
mothers whose perceptions may be impacted by depression [6, 7]. The prevalent explanation 49 
for the co-occurrence of mood disorders in pregnancy and adverse outcomes for children is 50 
that the mood disorders drive changes in the fetus altering the health trajectory of the child, 51 
known as “fetal programming” [8]. However, we suggest an alternative mechanism, supported 52 
by recent data from our experimental animal studies [9, 10], which is that placental endocrine 53 
insufficiency alone causes both the mood disorder and the adverse outcomes – which we refer 54 
to as the “placental programming hypothesis”  (FIG 1). This hypothesis fits some aspects of 55 
the epidemiology of pregnancy, but has not been directly tested in clinical studies. Importantly, 56 
this placental mechanism does not exclude the possibility of changes to the fetus driven by 57 
other adversities or indeed by placental endocrine insufficiency.  58 
 59 
Maternal behaviour 60 
The placenta is a fetally-derived organ fundamental to pregnancy [11, 12]. In addition to 61 
transporting nutrients and moderating fetal exposure to maternal factors, the placenta is a 62 
super-endocrine organ involved in manufacturing vast quantities of polypeptide and steroid 63 
hormones to induce and maintain maternal adaptations in pregnancy, and prepare the mother 64 
for her role in caring for her infant [12]. In rodents, maternal adaptations during pregnancy 65 
include changes in behaviour such as increased appetite, increased anxiety and altered nest 66 
building and grooming. The greatest changes take place after birth with mothers focused on 67 
nurturing their offspring, providing food, warmth, shelter and protection [13]. Both virgin 68 
females and male rodents can assume parental behaviour but this response requires several 69 
days of exposure to the pups in order to be initiated. In contrast, new mothers are already 70 
primed by hormonal exposures during pregnancy to respond immediately to the presence of 71 
their offspring. Inappropriate maternal behaviour may result from intrinsic deficiencies in the 72 
mother, as has been reported in many genetically modified mouse models, or as a 73 
consequence of placental endocrine insufficiency [9, 10].  74 
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 75 
Placental hormones implicated in the induction of maternal behaviour 76 
Key hormones involved in pregnancy-associated behaviours are the lactogenic hormones 77 
pituitary prolactin and prolactin-related hormones manufactured by the placenta, sometimes 78 
referred to as placental lactogens (see later). Prolactin is secreted from the pituitary to act 79 
locally on the maternal brain whereas the placentally-derived lactogenic hormones are thought 80 
to gain access to the maternal brain via the cerebrospinal fluid [14]. Key studies in rodents 81 
have experimentally demonstrated the importance of lactogenic signalling for maternal 82 
behaviour. These studies involved the infusion of prolactin or placental lactogen directly into 83 
the brains of non-pregnant animals which resulted in the stimulation of aspects postpartum 84 
maternal behaviour such as pup retrieval [14-19]. Conversely, experimentally-induced low 85 
levels of prolactin in pregnancy have been linked to increased postpartum anxiety and 86 
decreased pup retrieval [20]. Lactogenic hormones are thought to mediate their activity, at 87 
least in part, via the maternal prolactin receptor (Prlr) [21]. Loss of function of Prlr in mice was 88 
shown to result in a deficit in maternal behaviour [22, 23] and, more precisely, loss of function 89 
of Prlr restricted to the medial preoptic area of the brain [24]. Signalling via Prlr is also required 90 
for the pregnancy-related increases in neurogenesis that take place within the subventricular 91 
zone, one of three regions of the brain where neurogenesis persists in adults [23, 25]. 92 
Lactogenic activity may impact pregnancy-related changes in neurogenesis in the subgranular 93 
zone located within the hippocampus [26, 27] but it is not known whether these hormones 94 
stimulate neurogenesis in the hypothalamus during pregnancy [28, 29]. Prolactin-related 95 
hormones expressed by the placenta are known to stimulate the production of the steroid 96 
hormones progesterone and oestrogens, which in mice requires steroidogenic enzymes 97 
expressed in the ovary [30, 31]. Steroid hormones are expressed throughout pregnancy and 98 
their combined action at term is critical in priming maternal caregiving [32]. The mouse 99 
placenta is potentially a direct source of neuromodulators implicated in maternal behaviour 100 
including dopamine [33-35], oxytocin [36-38], vasopressin [39] and serotonin [40]. These 101 
hormones are either directly expressed in the placenta or components of their synthesis 102 
pathways are expressed in the placenta [10]. The levels of expression are uniformly low [10]. 103 
However, placentally-derived serotonin has been shown to functionally impact fetal brain 104 
development [41-44] which suggests these hormones could target the offspring’s brain rather 105 
than the mother’s.  106 
 107 
Sites of placental hormone production in the placenta 108 
In mice there are 22 prolactin-related hormones expressed primarily from the placenta [45]. 109 
The considerable variation in expression levels of these placental hormones in the mature 110 
mouse placenta suggests some likely only function locally whereas others function as 111 
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endocrine signals to the mother, and potentially also the fetus although this has not been 112 
demonstrated experimentally. Many prolactin-related hormones are not formally considered 113 
to have lactogenic activity (placental lactogens) as they do not appear to have the ability to 114 
bind Prlr. Only prolactin family 3, subfamily d, members 1-3 (Prl3d1-3 aka PL-I) and prolactin 115 
family 3, subfamily b, member 1 (Prl3b1 aka PL-II) are known to signal via Prlr [21]. The major 116 
source of placental lactogenic activity in the first half of pregnancy are the primary and 117 
secondary parietal trophoblast giant cells (P-TGCs) [45] (FIG 2A). Primary P-TGCs arise 118 
directly from trophectoderm cells located opposite to the inner cell mass at the time of 119 
implantation whereas secondary P-TGCs arise from a region called the ectoplacental cone 120 
which is  derived from the layer of trophectoderm located over the inner cell mass [46, 47]. 121 
Both primary and secondary TGCs express Prl3d1-3, with highest expression from embryonic 122 
day (E) 6.5 to E9.5 [45].  The mature mouse placenta, which forms at around E9.5, is 123 
organised into three histological distinct regions: the maternally-derived decidual component, 124 
and the fetally-derived junctional and the labyrinth zones (FIG 2B). Placental hormones are 125 
expressed from seven distinct and identifiable lineages which include the glycogen cell lineage 126 
and spongiotrophoblast lineage which form the bulk of the junctional zone, and five TGC 127 
subtype (parietal-, canal-, channel-, spiral artery- and sinusoidal-) located in close contact with 128 
maternal cells [48-51]. Prl3b1 is expressed from all of these lineages except the glycogen cell 129 
lineage and the spiral artery-TGCs [45]. The spongiotrophoblast lineage is the most  130 
substantial endocrine lineage to express Prl3b1 in terms of cell number with an estimated 6.23 131 
× 106 cells present by E16.5 [52]. In addition to prolactin-related hormones, the 132 
spongiotrophoblast lineage expresses pregnancy specific glycoproteins (Psgs), a multigene 133 
gene family that contribute to the protection of the semiallotypic fetus from the maternal 134 
immune system and are involved in remodelling placental and maternal vasculature [53]. The 135 
spongiotrophoblast is therefore the major endocrine lineage of the mouse placenta. 136 
 137 
Regulation of placental hormone production by imprinted genes 138 
Individual placental hormones have been genetically targeted to study their function in the 139 
placenta. Targeted deletion of the prolactin-related genes Prl4a1 [54] and Prl7b1 [55] have 140 
minor effects on the placenta under normal conditions but major effects in response to 141 
stressors such as hypoxia. Targeted deletion of Prl7d1 results in a reduction of the labyrinth 142 
and gain in the junctional zone with a sex specific increase in the number of glycogen cells in 143 
the male placenta [56]. Placental hormone levels can be manipulated en mass through the 144 
genetic modification of imprinted genes which regulate the number of placental cells 145 
expressing hormones [57]. Genomic imprinting describes genes expressed only from one 146 
parental allele as a consequence of epigenetic marks acquired in the germline [58]. Imprinting 147 
is thought to have evolved in mammals in response to the conflict imposed by pregnancy and 148 
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lactation, with maternal contributions to offspring significantly exceeding paternal contributions 149 
[59]. Given the function of placental hormones in ensuring nutrient allocation to the fetus, it is 150 
not surprising that genomic imprinting has influenced the expression of these hormones. 151 
Placental hormones can be directly imprinted, as is the case for one prolactin-related gene 152 
expressed in the placenta of the new world mouse, Peromyscus [60]. Expression of placental 153 
hormones is also indirectly regulated by imprinting because several genes controlling the 154 
development of the placental endocrine lineages are imprinted [57]. One of these genes is the 155 
maternally expressed/paternally silenced Pleckstrin Homology-Like Domain, Family A, 156 
Member 2 (Phlda2) gene. Loss-of-imprinting of Phlda2 (two-fold increased expression) 157 
reduces the contribution of the spongiotrophoblast lineage to the mature placenta by ~50% 158 
[61, 62]. Loss-of-expression of Phlda2 results in a two-fold expansion of this lineage [62]. As 159 
the spongiotrophoblast lineage expresses a number of prolactin-related hormones [45, 48], 160 
these manipulations decrease or increase, respectively, all the genes expressed from this 161 
lineage, which include Prl3b1 [62]. The maternally expressed/paternally silenced Achaete-162 
scute complex homolog 2 (Ascl2 aka Mash2) is required for the proper formation of placental 163 
endocrine lineages [63, 64] and overexpression of this gene functions to restrict the expansion 164 
of both the P-TGCs and the spongiotrophoblast [65]. A third maternally expressed/paternally 165 
silenced gene, Cyclin dependent kinase inhibitor 1c (Cdkn1c), functions to prevent over 166 
proliferation of a number of placental lineages [66] and is specifically required for the proper 167 
differentiation of the spongiotrophoblast and the S-TGCs [67]. While maternally 168 
expressed/paternally silenced genes primarily act to constrain the production of placental 169 
hormones, paternally expressed/maternally silenced genes appear to function antagonistically 170 
to promote placental signalling. Loss-of-imprinting (two-fold expression) of the paternally 171 
expressed/maternally silenced Insulin-like growth factor 2 (Igf2) gene results in a larger 172 
labyrinth region with double the number of glycogen cells and more than double the number 173 
of P-TGCs, although with no effect on the spongiotrophoblast [68]. Loss-of-expression of 174 
Paternally expressed gene 3 (Peg3) results in 50% fewer spongiotrophoblast cells and 40% 175 
fewer glycogen cells in male mutant placenta with female mutant placenta having a 176 
significantly attenuated placental lineage phenotype, with fewer overall changes in the 177 
expression levels of individual placental hormones [69]. Peg3 is known to function as a 178 
transcriptional repressor of a subset of placental hormone genes with loss of function resulting 179 
in increased expression in the brain [70]. As Peg3 encodes a positive regulator of placental 180 
lineage development and a negative regulator of a subset of placental hormones, loss-of-181 
expression of Peg3 in the placenta simultaneously decreases in the number of cells 182 
expressing hormones and increases the expression of a subset of hormones from the 183 
remaining cells [69]. Because of this sexual dimorphism, the more severe loss of placental 184 
cells in the male placenta is not counterbalanced by increased expression of some hormones 185 
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whereas in the female placenta fewer cells are lost and some hormones are expressed overall 186 
at higher than normal levels. As previously reviewed, there are a number of other genes 187 
paternally silenced by virtue of their location on the paternally inactivated X chromosome that 188 
regulate placental endocrine lineages [12]. The finding that several imprinted genes control 189 
the production of placental hormones by modulating the number of endocrine cells in the 190 
placenta has provided a tool to experimentally assess the function of placental hormones in 191 
inducing maternal behaviour, predicted by many indirect experiments.  192 
 193 
Impact of different doses of Phlda2 in the placenta on the behaviour of wild type dams 194 
Phlda2 is considered a negative rheostat for placental hormones because two-fold expression 195 
of Phlda2 results in a 50% loss of the spongiotrophoblast lineage whereas loss-of-expression 196 
of Phlda2 (maternal inheritance of Phlda2 targeted allele) results in a substantial 200% 197 
increase in the spongiotrophoblast lineage [62]. This rheostat function provided a system to 198 
test the behavioural consequences on dams after exposure to different levels of 199 
spongiotrophoblast-expressed placental hormones [10]. In this study, embryos expressing 200 
different doses of Phlda2, obtained by mating genetically modified parents, were surgically 201 
transferred into pseudopregnant wild type female mice (recipient transfer) to generate 202 
genetically wild type dams carrying offspring with either two active alleles (loss-of-imprinting; 203 
low hormone levels), one active allele (normal imprint; normal hormone levels) or no active 204 
allele (loss of maternal allele; high hormone levels) of Phlda2. Dams exposed to either 205 
abnormally low or abnormally high levels of placental hormones showed gene changes in the 206 
hypothalamus, important for the onset, maintenance and regulation of maternal behaviour, 207 
and the hippocampus, important for memory, learning and responses to fear and stress [71]. 208 
Alterations in G protein-coupled receptors (GPCR) pathways, olfactory transduction pathways 209 
and the gonadotropin-releasing hormone signalling pathway were consistent with the maternal 210 
brain responding to the different levels of placental hormones. Importantly, these changes 211 
were present before the dams gave birth. After birth, dams were able to care for their 212 
newborns, effectively make nests and gather their pups within the nest, and all pups gained 213 
weight indicative of adequate maternal caregiving. However, when the dams were challenged 214 
with either a pup retrieval task or a nest building task, those exposed to the highest levels of 215 
placental hormones in pregnancy performed less well than either the control group or the 216 
dams exposed to the lowest levels of hormones. In the disturbed situation (nest building task) 217 
dams exposed to the lowest levels of placental hormones prioritised nest building, neglecting 218 
their pups and themselves. In contrast, dams exposed to the highest levels of placental 219 
hormones prioritised caring for their pups and self-directed nurturing over the nest building. 220 
The presence of pups is important for the manifestation of maternal behaviour and any 221 
mutation impacting pup characteristics has the potential to result in a secondary effect on 222 
 7 
maternal behaviour [13, 72]. From birth pups begin communicating to their mothers using 223 
clicks and whistles. These ultrasonic vocalisations (USVs) increase in intensity and frequency 224 
when pups are separated from their mothers - hence the alternative and more forlorn term - 225 
“whistles of loneliness”  [73]. USVs are known to induce maternal behaviours such as nest 226 
building, pup retrieval and nursing [74-77]. However, no difference in USVs was noted for the 227 
Phlda2 mutant pups. Moreover, exposed dams continued to exhibit heightened maternal 228 
caregiving when presented with wild type pups taken from a different litter indicating the 229 
prenatal programming of behavioural changes. Together, these data indicate that hormones 230 
expressed from the spongiotrophoblast lineage play an important role in determining the 231 
priorities of the new mother. These experiments did not identify the specific hormone 232 
modulating maternal caregiving. Previous studies suggest that candidate is likely to be Prl3b1 233 
[22, 23], but it is possible that other hormones are involved. Irrespective of the exact hormone, 234 
this was the first physiologically relevant experiment to demonstrate that the integrity of the 235 
placental endocrine compartment is importance for maternal caregiving. In this experiment, 236 
placental endocrine insufficiency was found to result in suboptimal maternal care, at least 237 
during stressful situations. Two-fold expression of Phlda2 has previously been demonstrated 238 
to restrict fetal growth resulting in asymmetric low birth weight [78]. This model therefore 239 
combines placental endocrine insufficiency with low birth weight and suboptimal maternal care 240 
(FIG 3). 241 
 242 
Regulation of Phlda2 243 
Phlda2 is a maternally expressed imprinted gene which is not directly DNA methylated either 244 
in the germline or somatic tissues [79, 80]. Allelic expression is established through a germline 245 
acquired DNA methylation imprint which occurs more that 200 kilobases away from Phlda2 246 
[81] and is maintained by repressive histone modifications [82]. Expression of PHLDA2 in 247 
primary term human trophoblasts is reduced under conditions of hypoxia [83] and potentially 248 
increased in human placenta in relation to smoking [84] and strenuous exercise [85]. In animal 249 
models, increased placental Phlda2 has been reported in response to maternal alcohol [86] 250 
and maternal undernutrition in the form of low protein diet before and during pregnancy [87]. 251 
Consequently, there is potential for expression of Phlda2 to be modulated by environmental 252 
factors that act on the normally active maternal allele or potentially relax silencing of the 253 
paternal allele, to then influence the production of placental hormones. 254 
 255 
Impact of loss-of-expression of Peg3 in the placenta on the behaviour of wild type dams 256 
Peg3 functions antagonistically to Phlda2 as loss-of-expression (paternal inheritance of 257 
Phlda2 targeted allele) results in a substantial 50% decrease in the spongiotrophoblast lineage 258 
[69]. Peg3 is one of many genes where disruption in the dam results in a maternal care deficit 259 
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[88]. However, loss of function of Peg3 in the placenta also appears to have consequences 260 
for maternal behaviour [9]. In this study natural matings were used to generate all wild type 261 
pregnancies and pregnancies where the dam was wild type but all the pups were 262 
heterozygous for paternal loss-of-expression of Peg3. No detectable differences in 263 
transcriptional signature of the maternal hypothalamus or the hippocampus were present four 264 
days before birth, in contrast to the Phlda2 model where wild type dams showed changes in 265 
both these regions of the maternal brain at the same point in pregnancy [10]. During the 266 
pregnancy, there were no differences in nest building, anxiety-related behaviour or locomotor 267 
activity but pregnant dams carrying Peg3 mutant fetuses travelled significantly less distance 268 
when first transferred to a novel environment. After the pups were born, dams caring for 269 
mutant pups were slower to sniff and to retrieve pups. Dams were equally good at making 270 
nests and there were no changes in pup-directed behaviour or self-directed behaviours during 271 
the distracting nest building task. Also, in contrast to the Phlda2 model, dams mothering 272 
mutant Peg3 pups displayed heightened anxiety-related behaviour. Peg3 mutant pups were 273 
found to call less to their mothers, with a significant decrease in USVs. This deficit in 274 
communication may underlie the delay in pup retrieval and potentially also the heightened 275 
anxiety. However, the subtle changes in maternal behaviour that were detectable before the 276 
pups were born indicate some element of prenatal programming by the placenta. More 277 
extreme changes may not have been observed in this model due to the sexually dimorphic 278 
impact of loss of expression of Peg3 in the placenta [69] with the presence of the less impacted 279 
female placentas compensating for the defect in the male placenta. Currently, it is not possible 280 
to test this hypothesis as mouse litters are composed of both males and females. It will also 281 
be important to determine to what extent the placental defect versus the communication deficit 282 
contribute to the altered maternal behaviour after birth.  Nonetheless, this is a second example 283 
where placental endocrine insufficiency [69] is found in combination with low birth weight [88] 284 
and alterations in maternal behaviour (FIG 3). Appropriate expression of Peg3 in the brain and 285 
the placenta is therefore important for maternal behaviour. 286 
 287 
Humans 288 
These studies in mice highlight the functional importance of placental hormones in the 289 
induction of maternal caregiving, and the potential for placental endocrine insufficiency to 290 
contribute to suboptimal maternal care and anxiety, at least in mice. This raises the possibility 291 
that placental endocrine insufficiency could contribute to mood symptoms in a human 292 
pregnancy as a consequence of the mis-priming of the mother’s brain. There are clear and 293 
significant differences between mice and humans in their placentae [89] (FIG2 C). The human 294 
and mouse placenta are both haemochorial with the fetally-derived trophoblast cells in direct 295 
contact with the maternal blood and with cells that invade the maternal uterine wall but they 296 
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do not have the same morphologically equivalent structures [47]. Mouse placenta are 297 
composed of three major regions whereas human placenta possess villi bathed by maternal 298 
blood located in an intervillous space. Villi are composed of a single outermost layer of 299 
syncytiotrophoblast cells over a layer of villous cytotrophoblast cells both of which encase a 300 
core of mesenchymal cells, fetal blood vessels and Hofbauer cells with some similarity to the 301 
mouse labyrinth zone. Cytotrophoblast cell columns protrude from these villi, anchoring them 302 
to the maternal decidua. At the end of these columns there are extravillous cytotrophoblast 303 
cells which are an invasive cell type with potential similarity to mouse spiral artery trophoblast 304 
giant cells. The syncytiotrophoblast layer is the major site of the synthesis and secretion of 305 
placental hormones [90, 91] and recent single cell RNAseq analysis identified the extravillous 306 
cytotrophoblast as another a major site for the production of hormones [92].  307 
 308 
Both the mouse and human placenta express hormones related to prolactin, which shares an 309 
ancestral gene with growth hormone. In mice these are the 22 prolactin family members which 310 
arose from duplication of the prolactin gene whereas in humans four genes expressed in the 311 
placenta arose from duplication of the growth hormone gene which are chorionic 312 
somatomammotropin 1 (CSH1; aka hPL-A), chorionic somatomammotropin 2 (aka hPL-B), 313 
chorionic somatomammotropin like hormone (CSHL; aka hPL-L) and placental growth 314 
hormone (pGH; aka growth hormone variant; GH-V) [93, 94]. References to these hormones 315 
in the literature can be confusing due to the generic term “placental lactogen” which is refers 316 
to hPL-A/B in humans and to Prl3d1-3 or Prl3b1 in rodents, defined by the ability of these 317 
hormones to signal via Prlr. 318 
 319 
In rodents prolactin secretion from the pituitary is stimulated by the act of mating and provides 320 
the major lactogenic activity for the first half of pregnancy [95, 96]. As the placental lineages 321 
develop and expand, prolactin is replaced by Prl3d1-3 and then /Prl3b1 from mid-gestation 322 
until just prior to delivery [45] when there is a second surge in prolactin [97]. In contrast, in a 323 
human pregnancy prolactin and placental lactogen appear to increase linearly throughout 324 
pregnancy [98, 99] albeit with hPL present at higher levels than prolactin in maternal serum at 325 
term (5–7 vs. 0.15–0.18 µg/ml)  [93].  326 
 327 
Like the mouse placenta, the human placenta has the capacity to synthesis neuromodulators 328 
[92]. However, in contrast to the mouse, the human placenta directly synthesise progesterone 329 
and oestrogens through expression of steroidogenic enzymes.  330 
 331 
Evidence for placental endocrine insufficiency in maternal mood disorders 332 
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Maternal serum hPL levels and placental hPL expression have previously been shown to be 333 
significantly reduced in pregnancies complicated by fetal growth restriction [100, 101] which 334 
can co-occur with prenatal depression and anxiety. Similarly, low hPL has been reported in 335 
association with maternal obesity [102, 103] which is a risk factor for depression and anxiety 336 
in pregnancy [104]. We reported significantly lower levels of maternal serum hPL in 337 
pregnancies where mothers gave birth to small for gestational age infants, alongside higher 338 
expression of PHLDA2 in placenta [105] consistent with our observations in the mouse model. 339 
Low levels of maternal serum prolactin have been reported in human mothers with postnatal 340 
depression symptoms [106, 107] and increased levels in mothers with lower anxiety symptoms 341 
during pregnancy [108]. We reported lower placental hPL expression in prenatal depression 342 
[109]. In this study we reported lower placental expression of PEG3 in male infants [109]. More 343 
recently, we have reported that lower serum hPL at term is associated with higher symptoms 344 
of postnatal depression and anxiety exclusively in mothers of girls [110]. In the context of our 345 
findings in mouse models, these data suggest that insufficiency in hPL can contribute to 346 
maternal mood symptoms in a human pregnancy. Higher levels of placental corticotrophin 347 
hormone, which acts via the pituitary to stimulate release of cortisol (stress hormone) from the 348 
maternal adrenal gland, have been associated with postpartum depression [111]. While 349 
evidence for the involvement of steroid hormones in depressive or anxiety mood disorder is 350 
conflicting lower levels of allopregnanolone, a neuroactive metabolite of progesterone, have 351 
been associated with a lower risk of developing postpartum depression [112]. 352 
 353 
Conclusion 354 
In conclusion, studies in mice directly demonstrate that placental endocrine insufficiency can 355 
lead to low birth weight, alterations in maternal behaviours and increased anxiety symptoms.  356 
Indirect evidence suggests the potential for placental endocrine insufficiency to contribute to 357 
low birth weight and mood symptoms in human pregnancies, potentially explaining their 358 
observed co-occurrence. However, only a comprehensive assessment of the full repertoire 359 
of hormone-related genes from pregnancies impacted by prenatal depression and anxiety 360 
will fully address this question. 361 
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 674 
FIGURE LEGENDS 675 
 676 
Figure 1. Placental programming hypothesis. Both the fetus and the placenta are exposed 677 
to adversities in pregnancy. Adversities driving changes in the endocrine function of the 678 
placenta may impact fetal growth through reduced nutrient supply resulting in low birth weight. 679 
Placental endocrine insufficiency may also prevent the appropriate adaptations of the 680 
maternal brain required for motherhood manifesting as symptoms of depression and anxiety. 681 
Continued exposure of the offspring to maternal mood symptoms may further contribute to 682 
poor outcomes for children. 683 
 17 
 684 
Figure 2. Placental endocrine lineages. A. In mice, the major source of placental lactogenic 685 
activity between embryonic day (E6.5) and E9.5 is encoded by the prolactin-related Prl3d1-3 686 
genes expressed most highly in the primary and secondary parietal trophoblast giant cells. B. 687 
From E9.5 to term in mice, the major source of lactogenic activity is Prl3b1 expressed in seven 688 
placental lineages including the spongiotrophoblast. C. In human placenta, the major source 689 
of lactogenic hormones are the syncitiotrophoblast and the extravillus cytotrophoblast which 690 
express genes encoding human placental lactogen (CSH1/hPL-A and CSH2/hPL-B) 691 
 692 
Figure 3. Imprinted genes modulate the production of placental hormones. Studies in 693 
mice suggest that the silencing of genes in the male germline may have increased the number 694 
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of cells expressing placental hormones, and increased care provision by the mother to the 695 
offspring.  Conversely, silencing of imprinted genes in the female germline may have limited 696 
the number of cells expressing placental hormones, potentially to preserve maternal resources 697 
for subsequent pregnancies. Placental endocrine insufficiency in mice results in low birth 698 
weight, suboptimal maternal care and maternal anxiety  699 
 700 
 701 
 702 
